**Jan Novak**

Jan Novak is a Professor in the Department of Microbiology at the University of Alabama at Birmingham (UAB), Birmingham, AL, USA. He received his BS and MS in Biology from the Charles University, Prague, Czech Republic and PhD in Cell and Molecular Biology from the Czech Academy of Sciences. He has been at UAB since 1992. He was appointed to the rank of Distinguished Professor in 2022.

Dr. Novak's research interests include glycoimmunobiology and functional glycomics in health and disease, informing the emerging field of Glycomedicine. Major topics include renal and autoimmune diseases, cancer, mucosal infections, and biologically active compounds. Dr. Novak has been involved in many collaborative interdisciplinary studies, including those related to IgA nephropathy. These studies and related discoveries led to a multi-hit hypothesis for the pathogenesis of IgA nephropathy, a current "roadmap" for the development of disease-specific treatment and biomarkers.

Dr. Novak is an active member of the American Society of Nephrology (ASN) and a member of a steering committee of the International IgA Nephropathy Network. He is a member of the editorial board and an Associate Editor for the journal *Kidney Diseases*. In 2012, he co-organized an ASN early program, a 2-day conference on alloimmunity and autoimmunity. In 2013, he co-organized at UAB a mini-symposium "Glycoimmunobiology 2013", and in 2018 together with several colleagues at UAB established a new advanced course "Glycosylation in health and diseases". In 2021, he and his colleagues were invited by the NIH Glycobiology Scientific Interest Group to present a Special Topics Seminar Series on "Glycosylation in Human Health and Disease".

## *Editorial* **Special Issue: New Insights into the Pathogenesis and Therapies of IgA Nephropathy**

**Hitoshi Suzuki 1,\* and Jan Novak 2,\***


IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide [1]. Up to 40% of IgAN patients progress to kidney failure within 20 years following diagnosis [2]. Moreover, life expectancy is reduced by a decade in patients with IgAN [3]. IgA vasculitis with nephritis (IgAVN), formerly known as Henoch–Schönlein purpura nephritis, is a systemic form of vasculitis with renal manifestations similar to IgAN and with variable clinical outcome [4]. Thus, IgAN and IgAVN are significant public health problems.

The pathologic assessment of a renal biopsy specimen is the current "gold standard" for diagnosis of IgAN (for review, see [5–9]). Routine immunofluorescence reveals presence of glomerular immunodeposits consisting of IgA, with variable IgG and/or IgM. Complement C3 is present in most cases, but C1q is absent. Light microscopy provides an assessment of disease severity and prognosis based on the Oxford classification system. Its expanded version, termed MEST-C score, provides an evaluation of five different features: Mesangial cellularity, Endothelial hypercellularity, Segmental sclerosis, Tubular atrophy/interstitial fibrosis, and Crescents. IgAVN presents, in addition to kidney vasculitis features, with a greater frequency of severe lesions, such as glomerular necrosis and crescents. However, the pathologic findings for patients with IgAN as well as IgAVN may be impacted by the time between disease onset, diagnostic renal biopsy, and prior medications. Thus, a renal biopsy provides a snap shot in time since the inherent risks associated with renal biopsy hinder the use of a repeat biopsy. Minimally invasive approaches, such as those based on liquid biopsy biomarkers (e.g., blood, urine), are needed for monitoring disease progression, responses to treatments, and the identification of patients at risk of disease progression who may benefit from participation in new clinical trials.

In the last two decades, extensive studies, using genetic, cellular, biochemical, and immunologic approaches, have enabled the formulation of a multi-hit pathogenesis model for IgAN [10], which has been expanded to IgAVN [11]. This hypothesis postulates that glomerular immunodeposits originate from circulating immune complexes consisting of aberrantly glycosylated IgA1 bound by IgG autoantibodies. This IgA1 has some of the 3 to 6 clustered hinge-region *O*-glycans deficient in galactose (galactose-deficient IgA1). These IgA1-IgG circulating immune complexes have been found in patients with IgAN as well as IgAVN. Moreover, glomerular immunodeposits of patients with IgAN are enriched in galactose-deficient IgA1 glycoforms and the corresponding IgG autoantibodies [12–14]. Furthermore, the elevated serum levels of galactose-deficient IgA1 and corresponding IgG autoantibodies predict disease progression. The pathogenic role of immune complexes consisting of galactose-deficient IgA1 and IgG autoantibodies was recently confirmed in an experimental animal model [15,16]. Moreover, there are genetic elements involved in disease susceptibility and progression that can be associated with this multi-step mechanism [17–23].

Despite the progress since the disease was initially described in 1968 [24], diseasespecific therapy to slow or prevent the progression of kidney injury is still not available. To

**Citation:** Suzuki, H.; Novak, J. Special Issue: New Insights into the Pathogenesis and Therapies of IgA Nephropathy. *J. Clin. Med.* **2022**, *11*, 4378. https://doi.org/10.3390/ jcm11154378

Received: 19 July 2022 Accepted: 24 July 2022 Published: 28 July 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

develop a curative treatment, new strategies for early diagnosis, disease-specific targets, and methods for the assessment of clinical responses in clinical trials need to be identified and developed.

This Special Issue presents a collection of reviews and clinical and experimental studies focused on specific aspects of the current research of the diagnosis, prognosis, disease pathogenesis, determination of disease activity, and emerging strategies for the treatment of IgAN and IgAVN. Of the twelve papers in this Special Issue, two are focused on IgAVN, nine on IgAN, and one makes a comparison between IgAN and IgAVN. Two papers are related to pathology, specifically, the prognostic significance of crescents in IgAN (Trimarch et al. [25]) and the light microscopic features observed at different times since disease onset in adult patients with IgAVN (Lai et al. [26]). Another paper compares features of IgAN and IgAVN (Pillebout et al. [27]). Two reviews focus on the two key factors in IgAN, the autoantigen (galactose-deficient IgA1) and the corresponding autoantibodies (Ohyama et al. and Knoppova et al. [28,29]), whereas an experimental study postulates that urinary galactose-deficient IgA1 may be a disease-specific biomarker useful for the assessment of disease activity in IgAN (Fukao et al. [30]). Two additional studies consider the role of complement in disease pathogenesis as it relates to therapeutic approaches or the diagnosis and prognosis of disease progression (Poppelaars et al. and Mizerska-Wasiak et al. [31,32]). Another study postulates that obesity may play a role in mesangial lesions in IgAN (Hong et al. [33]). In the last three papers, the authors review the characteristics of various murine models of IgAN (Wehbi et al. [34]) and provide updates on the current clinical trials in IgAN (Cheung et al. [35] and Maixnerova et al. [36]).

Although the papers in this Special Issue do not cover all current activities in the field, we found these publications to be inspirational and informative. We hope that the readers of this Special Issue will reach the same conclusion.

**Author Contributions:** H.S. and J.N. worked together on the initial draft and its further editing. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** H.S. and J.N. are co-inventors for a US patent application 14/318,082 (assigned to UAB Research Foundation). J.N. is a co-founder and co-owner of and consultant for Reliant Glycosciences, LLC.
